Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well mosunetuzumab and polatuzumab vedotin works in treating patients with grade 1-3a follicular lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Polatuzumab vedotin is a monoclonal antibody, polatuzumab, linked to a toxic agent called vedotin. Polatuzumab attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Giving mosunetuzumab and polatuzumab vedotin may kill more cancer cells in patients with relapsed or refractory grade 1-3a follicular lymphoma.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Potwierdzony rozpoznaniem chłoniaka grudkowego stopnia 1-3a
- •Choroba wróciła po poprzednim leczeniu lub nie reaguje na dotychczasowe leczenie
- •Zmienne nowotworu muszą wykazywać obecność markera CD20
- •Wymaga leczenia z medycznego punktu widzenia
- •Możliwość zmierzenia zmian nowotworowych w badaniach obrazowych
- •Pełne wyzdrowienie z wcześniejszych efektów ubocznych leczenia
- •Odpowiednie parametry krwi (liczba neutrofili)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (2)
City of Hope Medical Center
Duarte, United States
City of Hope Orange County Lennar Foundation Cancer Center
Irvine, United States
Trial contact
Matthew Mei, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.